PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [7]: C07D 295/155, 295/135, A61K 31/445, 31/495, A61P 3/06, 9/10 — A1

(11) International Publication Number: WO 00/32582

(43) International Publication Date: 8 June 2000 (08.06.00)

(21) International Application Number: PCT/EP99/09320

(22) International Filing Date: 1 December 1999 (01.12.99)

(30) Priority Data:
9826412.0 3 December 1998 (03.12.98) GB

(71) Applicant *(for all designated States except US)*: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).


(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: DAUGAN, Alain, Claude-Marie [FR/FR]; Laboratoire Glaxo Wellcome, Centre de Recherches, ZA de Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis (FR).

(74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS



(I)

(57) Abstract

The invention relates to therapeutic benzamide compounds of formula (I) wherein A represents N or CH; X is selected from the following groups: (i) $-C_{1-6}$alkylene–, optionally containing one or two double bonds and optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6}acyl or C_{1-6}acyloxy groups, (ii) oxo, sulfonyl, thioxo, (iii) $-C_{1-6}$alkylenecarbonyl–, $-C_{1-6}$alkylenesulfonyl–, $-C_{1-6}$alkylenethioxo–, (iv) $-C_{2-6}$alkyleneoxy–, $-C_{2-6}$alkylenethio–, $-C_{2-6}$alkylene(N–H or N–C_{1-6}alkyl)amino–, (v) $-C_{1-6}$alkylenecarboxy–, $-C_{1-6}$alkylenethioamido–, $-C_{1-6}$alkylene(N–H or N–C_{1-6}alkyl)carboxamido–, and (vi) $-C_{2-6}$alkyleneoxycarbonyl–, $-C_{2-6}$alkylenethiocarbonyl–, $-C_{2-6}$ alkylene(N–H or N–C_{1-6}alkyl)aminocarbonyl–; Z represents a direct link or $-C_{1-6}$ alkylene–, optionally containing one double bond and optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} acyl or C_{1-6} acyloxy groups; R^1 is selected from the following groups: (i) hydrogen, C_{1-3}perfluoroalkyl, (ii) C_{6-10} aryl, C_{3-8}cycloalkyl and fused benz derivatives thereof, C_{7-10}polycycloalkyl, C_{4-8}cycloalkenyl, C_{7-10}polycycloalkenyl, (iii) a heterocyclyl selected from the group consisting of monocyclic radicals and fused polycylic radicals, and (iv) where either X is C_{1-6}alkylene and Z is a direct link, or Z is C_{1-6}alkylene, R^1 additionally may represent a halogen, cyano, nitro or C_{1-6}acyl group, wherein, when R^1 contains one or more rings, said rings may each independently bear 0 to 4 substituents. Y represents a direct or oxy link, $-C_{1-6}$alkylene–, –oxyC_{1-6}alkylene– or a heterocyclyl consisting of monocyclic radicals. R^2 represents phenyl, C_{3-8}cycloalkyl, or a heterocyclyl consisting of monocyclic radicals, and where each R^2 is optionally substituted by one or more groups independently selected from halogen, C_{1-4}alkyl, C_{1-4}alkoxy, C_{3-8}cycloalkyl, C_{1-3}perfluoroalkyl, C_{1-4}perfluoroalkoxy, hydroxycarbonyl, C_{1-6}alkoxycarbonyl, cyano, nitro, C_{1-4}alkylaminosulfonyl; R^3 represents hydrogen or one or more groups independently selected from halogen, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-3} perfluoroalkyl or C_{1-3} perfluoroalkoxy; or a physiologically acceptable salt, solvate or derivative thereof, pharmaceutical compositions, to processes for their preparation and their use in the treatment of conditions mediated by ApoB-100 regulation.